AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$CMPX

Lerner Neil purchased $18K of CMPX

Lerner Neil (Chief Accounting Officer) purchased 20,000 shares of Compass Therapeutics, Inc. (CMPX) at $0.92 on 2026-10-01.

Original reporting
SEC EDGAR · Lerner Neil
Published Oct 2, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CMPX
Neutral
medium confidence
Mentioned
$CMPX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMPXNeutralLow
01

Why it matters

The filing is a primary source but the transaction size is small, offering limited trading insight.

02

Market read

Insider purchase is a routine disclosure with low material impact on the stock.

03

What to watch

No accompanying corporate news or price movement suggests limited relevance.

Relevance 4/10Novelty 5/10Timing: pre-market today

Background

SEC Form 4 filing discloses an insider purchase by a senior officer of Compass Therapeutics.

Company-level read

Ticker impact

$CMPXNeutralMedium confidence
Context

Form 4 shows Chief Accounting Officer Lerner Neil bought 20,000 shares at $0.92, increasing his stake to 420,000 shares.

Expected impact

modest upward pressure as the market prices in the insider buy

Evidence & confidence

The transaction is a primary disclosure but the dollar amount ($18.4k) is trivial for a public company, so any price effect is likely limited.

Market effects

Sector

Minimal; insider activity does not materially affect the biotech sector.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong confidence signal.

Key entities

  • company
    Compass Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker CMPX.

  • person
    Lerner Neil

    Chief Accounting Officer of Compass Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMPX insider trading history →

Related articles

OCT 24
$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

investing.com2 min
OCT 24
$CMPXHighAI 8/10

A bile duct cancer trial found 56% lower risk of progression or death with a drug combination.

Compass Therapeutics (CMPX) reported positive results from the COMPANION-002 trial of tovecimig in combination with paclitaxel for advanced biliary tract cancer. The study met primary and key secondary endpoints, showing a 56% reduction in disease progression or death risk. The drug demonstrated durable responses and improved disease control rates. The safety profile was consistent with prior studies.

stocktitan.net2 min
SEP 22
$CMPXHighAI 9/10

CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing

Compass Therapeutics (CMPX) shares fell over 25% after the FDA recommended an additional trial for its cancer drug Tovecimig, potentially delaying its marketing application. The FDA wants a trial demonstrating improved overall survival in advanced biliary tract cancer patients. Compass disagrees and plans further discussions. The company has $180 million in cash, expected to last into 2028. CMPX shares traded at over 2-year lows.

stocktwits.com7 min